Results 161 to 170 of about 182,014 (348)

Body mass index as a predictive factor for efficacy of adjuvant taxane‐based chemotherapy in early‐stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies

International Journal of Cancer, Volume 157, Issue 4, Page 709-721, 15 August 2025.
What's new? Body mass index (BMI) potentially influences outcomes among women with early‐stage breast cancer (EBC). Little is known, however, about relationships between BMI and disease prognosis for different adjuvant taxane‐based chemotherapies. Here, the prognostic effect of BMI on disease recurrence was evaluated among EBC patients treated with ...
José A. García‐Saenz, Gonzalo Spera, Marina Pollán, Begoña Bermejo, Manuel Ruiz‐Borrego, Arlene Chan, Miguel Martín, Ángel Guerrero‐Zotano, Lourdes Calvo, Álvaro Rodríguez‐Lescure, María Marín, Linnea Chap, John Crown, Tadeusz Pienkowski, Valerie Bee, Maribel Casas, Óscar Polonio, Susana Bezares, Dennis Slamon   +18 more
wiley   +1 more source

Management of patients after mastectomy. [PDF]

, 1981
P. Clark, David L. Morris
openalex   +3 more sources

Nipple‑sparing mastectomies: Clinical outcomes from a single academic institution [PDF]

, 2017
Conant, Leah, Cyr, Amy, Dull, Barbara, Margenthaler, Julie A, Myckatyn, Terence, Tenenbaum, Marissa   +5 more
core   +2 more sources

THE TEN-YEAR SURVIVORS OF RADICAL MASTECTOMY

, 1933
Frank S. Mathews
openalex   +2 more sources

Modification of muscle-preserving radical mastectomy [PDF]

, 1979
Hiroshi Kodama
openalex   +1 more source

The TESTBREAST journey: Revisiting the importance of early detection by frequent screening of women at high risk of breast cancer

International Journal of Cancer, Volume 157, Issue 4, Page 741-751, 15 August 2025.
What's new? Women who are at high risk of breast cancer (BC), either because of a BRCA1/2 mutation or family history, require more aggressive screening. Here, the authors report on the clinical characteristics of the high‐risk women who developed BC during the TESTBREAST study. Of the 1108 participants, 124 (16.5%) developed breast cancer. Their median
Layla Andour, Sophie C. Hagenaars, Kiki Vangangelt, Janneke Aalberts, Valerie Rebattu, Dorien M. A. Berends van der Meer, Elma Meershoek‐Klein Kranenbarg, Katja N. Gaarenstroom, Christi J. van Asperen, Rob A. E. M. Tollenaar, Wilma E. Mesker, on behalf of the TESTBREAST study team, J. Aalberts, T. M. A. Berends‐van der Meer, S. C. Hagenaars, L. Andour, W.E. Mesker, R. A. E. M Tollenaar, W. M. Meershoek‐Klein Kranenbarg, K. N. Gaarenstroom, C. M. R. Haekens, K. B. M. I. Keymeulen, J. Remmelzwaal, M. Piek‐den Hartog, E. J. T. Rutgers, C. Drukker, C. Lemstra, A. Prozee, J. de Vries, A. Stam, C. Bandel, I. Meijer, A. E. Dassen, S. Makineli, E. E. van Oers‐Hazelzet, A. J. Witkamp, K. E. Schenk, W. van der Eijk, M. B. E. Menke‐Pluijmers, J. de Droog‐Laane, B. A. Kortmann   +40 more
wiley   +1 more source

SKIN REMOVAL IN RADICAL MASTECTOMY

, 1942
William C. White
openalex   +2 more sources

Response to neoadjuvant chemotherapy in early breast cancers is associated with epithelial–mesenchymal transition and tumor‐infiltrating lymphocytes

Molecular Oncology, Volume 19, Issue 8, Page 2330-2347, August 2025.
Epithelial–mesenchymal transition (EMT) and tumor‐infiltrating lymphocytes (TILs) are associated with early breast cancer response to neoadjuvant chemotherapy (NAC). This study evaluated EMT and TIL shifts, with immunofluorescence and RNA sequencing, at diagnosis and in residual tumors as potential biomarkers associated with treatment response.
Françoise Derouane, Jérôme Ambroise, Cédric van Marcke, Mieke Van Bockstal, Martine Berlière, Christine Galant, Hélène Dano, Médina Lougué, Elena Benidovskaya, Guy Jerusalem, Vincent Bours, Claire Josse, Jérôme Thiry, Aurélie Daumerie, Caroline Bouzin, Cyril Corbet, François P. Duhoux   +16 more
wiley   +1 more source

Using Machine Learning to Improve Control for Confounding in the Dynamic Weighted Ordinary Least Squares Estimator of Optimal Adaptive Treatment Strategies

Biometrical Journal, Volume 67, Issue 4, August 2025.
ABSTRACT Estimating optimal adaptive treatment strategies (ATSs) can be done in several ways, including dynamic weighted ordinary least squares (dWOLS). This approach is doubly robust as it requires modeling both the treatment and the response, but only one of those models needs to be correctly specified to obtain a consistent estimator. For estimating
Kossi Clément Trenou, Miceline Mésidor, Aida Eslami, Hermann Nabi, Caroline Diorio, Denis Talbot   +5 more
wiley   +1 more source